Scorpius Holdings Accepted as a Member of the US Government’s BioMaP-Consortium
14 Marzo 2024 - 1:30PM
Scorpius Holdings, Inc (NYSE
American: SCPX), an integrated contract
development and manufacturing organization (CDMO), today announced
that it has been accepted into the Biopharmaceutical Manufacturing
Preparedness Consortium (BioMaP-Consortium), a part of the National
Biopharmaceutical Manufacturing Partnership. The BioMap-Consortium
has a $20 billion funding ceiling, through which it provides growth
funding, as well as streamlined access to servicing
government-funded manufacturing programs.
The BioMaP-Consortium supports the Biomedical
Advanced Research and Development Authority (BARDA) and is
comprised of industry partners across the drug and vaccine
manufacturing supply chain, including manufacturers of raw
materials and consumables, developers of innovative manufacturing
technologies, and suppliers of fill finish services. This
consortium seeks to expand the industrial and manufacturing base
for medical countermeasures to include the requisite capabilities,
flexibilities, and strategies to secure needed medical supplies to
meet the nation’s public health preparedness and response
requirements.
Jeff Wolf, CEO of Scorpius, stated, "We are
honored to be accepted as a member of the BioMaP-Consortium, which
provides Scorpius opportunities to support biomanufacturing
programs focused on the nation’s medical countermeasure programs,
while providing biomanufacturing capacity and capabilities to
defend against pandemics and other emerging threats. We look
forward to building upon our track record of supporting infectious
disease and biodefense programs on behalf of BARDA, the U.S.
Department of Health & Human Services, and the U.S. Department
of Defense.”
Scorpius Holdings, Inc.
Scorpius Holdings Inc. is an integrated contract
development and manufacturing organization (CDMO) focused on
rapidly advancing biologic and cell therapy programs to the clinic
and beyond. Scorpius offers a broad array of analytical testing,
process development, and manufacturing services to pharmaceutical
and biotech companies at its state-of-the-art facilities in San
Antonio, TX. With an experienced team and new, purpose-built U.S.
facilities, Scorpius is dedicated to transparent collaboration and
flexible, high-quality biologics biomanufacturing. For more
information, please visit www.scorpiusbiologics.com.
Forward-Looking Statement
This release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. In some cases, forward-looking statements can be
identified by terminology such as "may," "should," "potential,"
"continue," "expects," "anticipates," "intends," "plans,"
"believes," "estimates," and similar expressions, and include
statements such as the Company’s opportunities to support
biomanufacturing programs focused on the nation’s medical
countermeasure programs, while providing biomanufacturing capacity
and capabilities to defend against pandemics and other emerging
threats and supporting infectious disease and biodefense programs
on behalf of BARDA, HHS and the DoD. Important factors that could
cause actual results to differ materially from current expectations
include, among others, the Company’s ability to expand its large
molecule biomanufacturing CDMO services and continue to grow
revenue; the Company’s financing needs, its cash balance being
sufficient to sustain operations and its ability to raise capital
when needed, the Company’s ability to leverage fixed costs and
achieve long-term profitability; the Company’s ability to obtain
regulatory approvals or to comply with ongoing regulatory
requirements, regulatory limitations relating to the Company’s
ability to successfully promote its services and compete as a
pure-play CDMO, and other factors described in the Company’s annual
report on Form 10-K for the year ended December 31, 2022,
subsequent quarterly reports on Form 10-Qs and any other filings
the Company makes with the SEC. The information in this
presentation is provided only as of the date presented, and the
Company undertakes no obligation to update any forward-looking
statements contained in this presentation on account of new
information, future events, or otherwise, except as required by
law.
Media and Investor Relations
ContactDavid Waldman+1 919 289
4017ir@scorpiusbiologics.com
Grafico Azioni Nighthawk Biosciences (AMEX:NHWK)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Nighthawk Biosciences (AMEX:NHWK)
Storico
Da Set 2023 a Set 2024